Clinical Omics – News and Features

Scientists and clinicians from the University of Cambridge – supported by Cancer Research UK (CRUK) – have conducted the largest whole-genome sequencing analysis of cancer tumors to date.

In this interview, Dr. Daniel Hornburg discusses how engineered nanoparticles could help to bridge the gap between proteomics and genomics and transform cancer diagnostics.

In this article, we will explore some of the recent advances in proteomics and their potential wider impact.

A new study has adopted a multi-omics methodology to explore potential links between diet, the microbiome and the immune response in multiple sclerosis (MS). The results are published in EBioMedicine.

Single-cell technologies are transforming our knowledge of human health and disease. In this article, Gary Kruppa outlines the latest advances in single-cell proteomics.

Researchers have uncovered 166 prognostic biomarkers through machine learning analysis of long non-coding RNAs.

A team of researchers has developed the largest and most comprehensive molecular map to date of lung squamous cell carcinoma. The database, which brings proteomic, transcriptomic and genomic data together, can be used to find potential new drug targets and identify underlying disease mechanisms related to therapy resistance.

In the early 20th century, mass spectrometry (MS) was used to measure the mass of atoms and demonstrate the existence of isotopes. Now, MS is used to study a broad range of molecules including small hydrocarbons, proteins, peptides, carbohydrates and DNA.

Researchers have analyzed more than 8,000 proteins in detail from fixed samples of lung cancer tissue using mass spectrometers.

In this article, we take a look at the fundamentals of mass spectrometry, how it works, variations that can be used at each stage of the process and how they can be combined to suit different sample types or analytical questions.